CN113801138A - Method for preparing lanimivir octanoate intermediate by one-pot method - Google Patents

Method for preparing lanimivir octanoate intermediate by one-pot method Download PDF

Info

Publication number
CN113801138A
CN113801138A CN202010532321.1A CN202010532321A CN113801138A CN 113801138 A CN113801138 A CN 113801138A CN 202010532321 A CN202010532321 A CN 202010532321A CN 113801138 A CN113801138 A CN 113801138A
Authority
CN
China
Prior art keywords
compound
reaction
formula
compound represented
octanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010532321.1A
Other languages
Chinese (zh)
Inventor
袁建栋
黄仰青
池建文
顾家宁
杭文明
林祥义
孙鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XINTAI PHARMACEUTICAL (SUZHOU) CO Ltd
Brightgene Bio Medical Technology Co Ltd
Original Assignee
XINTAI PHARMACEUTICAL (SUZHOU) CO Ltd
Brightgene Bio Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XINTAI PHARMACEUTICAL (SUZHOU) CO Ltd, Brightgene Bio Medical Technology Co Ltd filed Critical XINTAI PHARMACEUTICAL (SUZHOU) CO Ltd
Priority to CN202010532321.1A priority Critical patent/CN113801138A/en
Priority to PCT/CN2020/120751 priority patent/WO2021248764A1/en
Publication of CN113801138A publication Critical patent/CN113801138A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The invention relates to the technical field of drug synthesis, in particular to a method for preparing a lanimivir octanoate intermediate by a one-pot method. The invention relates to a method for preparing a lanimivir octanoate intermediate by a one-pot method, which comprises the step of adding a compound shown as a formula (4) in an R1OH、NaH、(R1O)2Reacting in the presence of CO to obtain a compound shown as a formula (5), R1Is benzyl, substituted benzyl or allyl. The method creatively adopts a one-pot method to synthesize the lanimivir octanoate intermediate compound (5) from the compound (4), the reaction is mild and rapid, the next reaction can be carried out by simple post-treatment, the energy consumption is saved, the pollution is reduced, the operation is simple, the cost is low, and the method is suitable for industrial production. The invention adopts a one-pot method to prepare the lanimivir octanoate intermediate compound (5), and the yield is up to more than 87%.

Description

Method for preparing lanimivir octanoate intermediate by one-pot method
Technical Field
The invention relates to the technical field of drug synthesis, in particular to a method for preparing a lanimivir octanoate intermediate by a one-pot method.
Background
Lanamivir octanoate (Laninavir) is a neuraminidase inhibitor developed by Biota Pharmaceuticals and Daiichi Sankyo, and can be used for treating influenza virus infection resistant to oseltamivir (Tamiflu). Approved in 2010 to be marketed in japan under the name Inavir.
The lanimivir octanoate has the following chemical structural formula:
Figure BDA0002535817500000011
the lanimivir octanoate has good effects on H1N1, H5N1, N9 and B type influenza viruses and Tamiflu-resistant viruses, and has not been marketed at home and registered by the manufacturer at present. In order to guide the research and development of the imitation drugs and improve the accessibility of the public drugs, the national food and drug administration drug evaluation center organization screens foreign marketed drugs which have expired, terminated and invalid internal compound patent rights and have no imitation applications, wherein the lanimivir octanoate is primarily screened and is included in the drug list which has expired, terminated and invalid first patent rights and has no imitation applications.
At present, the preparation method of the lanimivir octanoate is classified into the following three methods:
in the first method, patent CN101679339A discloses synthesis of lanimivir octanoate by using sialic acid as a starting material through 11 steps of reaction, wherein the synthetic route is as follows:
Figure BDA0002535817500000012
Figure BDA0002535817500000021
the route takes commercially supplied sialic acid as a starting material, and the lanimivir octanoate is synthesized through 11 steps of reaction, so that the unit reaction effect is good, and the overall yield is high.
In the second method, patent CN103435582A discloses a zanamivir as a starting material, and the synthesis of lanimivir octanoate through 5-step reaction is as follows:
Figure BDA0002535817500000022
although the method has few steps, the zannanovir is used as the starting raw material, and the price of the raw material is too expensive, so that the requirement of the imitation drugs is difficult to meet;
in the third method, the mawei task group takes D-isoascorbic acid as a starting material, and synthesizes lanimivir octanoate through manual catalytic cyclization and a series of reactions such as oxidation, reduction, protection, deprotection and the like, wherein the synthetic route is as follows:
Figure BDA0002535817500000031
the synthetic route is novel, the unit reaction yield is moderate, but the market supply of starting materials and catalyst ligands is less, the price is high, the method is not suitable for large-scale production, and simultaneously, the chiral purity of the intermediate S-3 and the intermediate S-8 is not high, so that more subsequent isomer impurities are caused, and the quality of a final product is difficult to control.
In the three routes, the raw material price of the second route is too expensive, and the reagent of the third route is too expensive, so that the method is not suitable for industrial production, so that the research is focused on the process optimization of the patent CN101679339A, concentrated sulfuric acid needs to be added in the process of producing the compound 3 in the patent in the repeated process of CN101679339A, the reaction conditions are harsh, and the risk in industrial production is high; the reaction steps in the production process of the compounds 4-6 are complicated, column chromatography is needed, the industrial production requirements are difficult to meet, and further optimization is needed.
Disclosure of Invention
The invention aims to provide a method for preparing a lanimivir octanoate intermediate by a one-pot method.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a method for preparing a lanimivir octanoate intermediate by a one-pot method adopts a synthesis method comprising the following steps:
Figure BDA0002535817500000041
wherein R is1Is benzyl, substituted benzyl or allyl.
The substituted benzyl group mentioned above means: the benzene ring on the benzyl is mono-substituted or multi-substituted by chlorine, bromine, iodine, nitro, alkoxy, alkyl, aryl and other groups.
The method for preparing the lanimivir octanoate intermediate by the one-pot method comprises the following steps: mixing a compound represented by the formula (4) with an organic solvent R1OH is mixed and stirred, then NaH is added under the protection of nitrogen, stirring is carried out for 30-60 min, and then (R) is added1O)2And (3) stirring CO at the temperature of 0-80 ℃ for reaction for 30 min-24 h, and then separating to obtain the compound shown in the formula (5).
The crude compound of formula (5) is crystallized from toluene or methanol to obtain crystals of the compound of formula (5).
Preferably, the reaction temperature is 10-60 ℃.
Further preferably, the reaction temperature is 50-55 ℃.
Preferably, the reaction time is 30min to 5 h.
The organic solvent is any one or more of toluene, N-dimethylformamide, benzyl alcohol, N-heptane, methyl tert-butyl ether, tetrahydrofuran and 1, 4-dioxane.
The mass concentration of NaH is 60%.
Preferably, R1Is benzyl.
In the above process, the formula (4) is shownCompound, R1OH、NaH、(R1O)2The mass ratio of CO is 8-12: 15-30: 0.02-0.1: 12-36. Preferably, a compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 9.8: 20: 0.04: 24.22.
the compound represented by the above formula (4) is synthesized by the following route:
Figure BDA0002535817500000042
wherein R is1Is benzyl, substituted benzyl or allyl, X is Cl-、Br-、I-、MeSO4 -、TfO-。
Step 1, in the presence of a base, reacting a compound represented by the formula (1) with R1X reacts to produce a compound represented by the formula (2).
The base is not particularly limited, and may be neutralized with a carboxylic acid, and may be an organic base or an inorganic base.
Preferably, the organic base is such as triethylamine, diisopropylethylamine, N-dimethyl-4-aminopyridine or pyridine; inorganic bases such as cesium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
An inorganic base is preferred, and cesium carbonate or potassium carbonate is further preferred.
Step 2, reacting the compound represented by formula (2) with acetic anhydride in the presence of an organic base to produce a compound represented by formula (3). The organic base is not limited and may be neutralized with a carboxylic acid.
Preferably, the organic base is any one or more of triethylamine, diisopropylethylamine, N-dimethyl-4-aminopyridine and pyridine.
The reaction temperature of the step 2 is-30 ℃ to 100 ℃. Preferably 0 to 35 ℃.
The reaction time of the step 2 is 30 min-24 h. Preferably 10-15 h.
Step 3, the compound represented by the formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce a compound represented by the formula (4).
And 3, the reaction temperature is 0-70 ℃. Preferably from 30 ℃ to 60 ℃.
The reaction time of the step 3 is 1.0-24 h. Preferably 1.0 to 3.0 hours.
And 3, dropwise adding triethylamine to the post-treatment in the step to quench the reaction.
A preparation method of lanimivir octanoate (a compound shown in a formula I) adopts a synthesis method comprising the following steps:
Figure BDA0002535817500000051
step 5 is a reaction of the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to give a compound represented by formula (6).
The reaction temperature in step 5 is 0 to 70 ℃ and preferably 0 to 30 ℃.
The reaction time of the step 5 is 30 min-24 h, preferably 1.0-15 h.
Step 6 is to react the compound represented by formula (6) with trimethylsilyl azide under catalysis of titanium isopropoxide to produce a compound represented by formula (7).
The reaction temperature in the step 6 is 0-120 ℃, and preferably 0-40 ℃.
The reaction time of the step 6 is 3.0-48 h, preferably 3.0-24 h.
Step 7 is a reaction of the compound represented by formula (7) with triphenylphosphine to give a compound represented by formula (8).
The reaction temperature in the step 7 is-10 to 80 ℃, and preferably 0 to 60 ℃.
The reaction time of the step 7 is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
Step 8 is a reaction of the compound represented by formula (8) with a base to give a compound represented by formula (9).
As the base, an inorganic base is preferable, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferable.
The reaction temperature in the step 8 is preferably-10 to 100 ℃, and more preferably 0 to 50 ℃.
The reaction time in step 8 is preferably 10 minutes to 48 hours, and more preferably 0.5 hour to 6 hours.
Step 9 is a reaction of the compound represented by formula (9) with the compound represented by formula (10) to give the compound represented by formula (11).
The step 9 reaction solvent is preferably purified water.
The reaction temperature in the step 9 is 0-100 ℃, and preferably 5-50 ℃.
The reaction time of the step 9 is 24-72 h, and preferably 24-60 h.
Step 10 is a reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to give the compound represented by formula (12).
The reaction temperature in the step 10 is-20 to 100 ℃, and preferably 0 to 45 ℃.
The reaction time of the step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
Step 11 is to react a compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, followed by reaction with water to produce a compound represented by formula (i) or a pharmacologically acceptable salt thereof.
The acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
The reaction temperature in the step 11 is preferably-10 to 70 ℃, and preferably 0 to 50 ℃.
The step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
Compound 13 and compound 14 can be prepared by prior art methods of preparation; it can also be prepared by the following route:
Figure BDA0002535817500000071
the invention has the beneficial effects that:
when CN101679339A is adopted to prepare the compound 3, concentrated sulfuric acid needs to be added, which is not suitable for industrial production, researchers find that TMSOTf can be used for better reaction, the aftertreatment is easy, and industrial pollution cannot be generated.
The method creatively adopts a one-pot method to synthesize the lanimivir octanoate intermediate compound (5) from the compound (4), the reaction is mild and rapid, the product does not need column chromatography, the next reaction can be carried out by simple post-treatment, the energy consumption is saved, the pollution is reduced, the operation is simple, the cost is low, and the method is suitable for industrial production.
The yield of the lanimivir octanoate intermediate compound (5) prepared by the one-pot method is up to more than 87%, and the yield of the lanimivir octanoate prepared by the intermediate is more than 85%. The method adopting CN101679339A has more impurities and needs column chromatography, and the yield of the two-step method is only 76.9%.
Drawings
FIG. 1 is a hydrogen spectrum of compound (2);
FIG. 2 is a hydrogen spectrum of compound (3);
FIG. 3 is a hydrogen spectrum of compound (4);
FIG. 4 is a hydrogen spectrum of compound (5);
FIG. 5 is a hydrogen spectrum of compound (6);
FIG. 6 is a hydrogen spectrum of compound (12);
fig. 7 is a hydrogen spectrum of compound (13).
Detailed Description
The invention relates to a method for preparing a lanimivir octanoate intermediate by a one-pot method, which adopts a synthesis method comprising the following steps:
Figure BDA0002535817500000072
wherein R is1Is benzyl, substituted benzyl or allyl.
The substituted benzyl group mentioned above means: the benzene ring on the benzyl is mono-substituted or multi-substituted by chlorine, bromine, iodine, nitro, alkoxy, alkyl, aryl and other groups.
The method for preparing the lanimivir octanoate intermediate by the one-pot method comprises the following steps: mixing a compound represented by the formula (4) with an organic solvent R1OH is mixed and stirred, then NaH is added under the protection of nitrogen, stirring is carried out for 30-60 min, and then (R) is added1O)2And (3) stirring CO at the temperature of 0-80 ℃ for reaction for 30 min-24 h, and then separating to obtain the compound shown in the formula (5).
The crude compound of formula (5) is crystallized from toluene or methanol to obtain crystals of the compound of formula (5).
Preferably, the reaction temperature is 10-60 ℃.
Further preferably, the reaction temperature is 50-55 ℃.
Preferably, the reaction time is 30min to 5 h.
The organic solvent is any one or more of toluene, N-dimethylformamide, benzyl alcohol, N-heptane, methyl tert-butyl ether, tetrahydrofuran and 1, 4-dioxane.
The mass concentration of NaH is 60%.
Preferably, R1Is benzyl.
In the above process, the compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 8-12: 15-30: 0.02-0.1: 12-36. Preferably, a compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 9.8: 20: 0.04: 24.22.
the compound represented by the above formula (4) is synthesized by the following route:
Figure BDA0002535817500000081
wherein R is1Is benzyl, substituted benzyl or allyl, X is Cl-、Br-、I-、MeSO4 -、TfO-。
Step 1, in the presence of a base, reacting a compound represented by the formula (1) with R1X reacts to produce a compound represented by the formula (2).
The base is not particularly limited, and may be neutralized with a carboxylic acid, and may be an organic base or an inorganic base.
Preferably, the organic base is such as triethylamine, diisopropylethylamine, N-dimethyl-4-aminopyridine or pyridine; inorganic bases such as cesium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide.
An inorganic base is preferred, and cesium carbonate or potassium carbonate is further preferred.
Step 2, reacting the compound represented by formula (2) with acetic anhydride in the presence of an organic base to produce a compound represented by formula (3). The organic base is not limited and may be neutralized with a carboxylic acid.
Preferably, the organic base is any one or more of triethylamine, diisopropylethylamine, N-dimethyl-4-aminopyridine and pyridine.
The reaction temperature of the step 2 is-30 ℃ to 100 ℃. Preferably 0 to 35 ℃.
The reaction time of the step 2 is 30 min-24 h. Preferably 10-15 h.
Step 3, the compound represented by the formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce a compound represented by the formula (4).
And 3, the reaction temperature is 0-70 ℃. Preferably from 30 ℃ to 60 ℃.
The reaction time of the step 3 is 1.0-24 h. Preferably 1.0 to 3.0 hours.
And 3, dropwise adding triethylamine to the post-treatment in the step to quench the reaction.
The preparation method of the lanimivir octanoate (compound shown in the formula I) adopts the following synthesis method:
Figure BDA0002535817500000091
step 5 is a reaction of the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to give a compound represented by formula (6).
The reaction temperature in step 5 is 0 to 70 ℃ and preferably 0 to 30 ℃.
The reaction time of the step 5 is 30 min-24 h, preferably 1.0-15 h.
Step 6 is to react the compound represented by formula (6) with trimethylsilyl azide under catalysis of titanium isopropoxide to produce a compound represented by formula (7).
The reaction temperature in the step 6 is 0-120 ℃, and preferably 0-40 ℃.
The reaction time of the step 6 is 3.0-48 h, preferably 3.0-24 h.
Step 7 is a reaction of the compound represented by formula (7) with triphenylphosphine to give a compound represented by formula (8).
The reaction temperature in the step 7 is-10 to 80 ℃, and preferably 0 to 60 ℃.
The reaction time of the step 7 is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
Step 8 is a reaction of the compound represented by formula (8) with a base to give a compound represented by formula (9).
As the base, an inorganic base is preferable, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferable.
The reaction temperature in the step 8 is preferably-10 to 100 ℃, and more preferably 0 to 50 ℃.
The reaction time in step 8 is preferably 10 minutes to 48 hours, and more preferably 0.5 hour to 6 hours.
Step 9 is a reaction of the compound represented by formula (9) with the compound represented by formula (10) to give the compound represented by formula (11).
The step 9 reaction solvent is preferably purified water.
The reaction temperature in the step 9 is 0-100 ℃, and preferably 5-50 ℃.
The reaction time of the step 9 is 24-72 h, and preferably 24-60 h.
Step 10 is a reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to give the compound represented by formula (12).
The reaction temperature in the step 10 is-20 to 100 ℃, and preferably 0 to 45 ℃.
The reaction time of the step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
Step 11 is to react a compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, followed by reaction with water to produce a compound represented by formula (i) or a pharmacologically acceptable salt thereof.
The acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
The reaction temperature in the step 11 is preferably-10 to 70 ℃, and preferably 0 to 50 ℃.
The step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
Compound 13 and compound 14 can be prepared by prior art methods of preparation; it can also be prepared by the following route:
Figure BDA0002535817500000111
example 1
The preparation of compound (2) comprises the following steps:
at normal temperature, 30.93g of N-acetylneuraminic acid (compound 1) and Cs are sequentially added into a 500ml reaction bottle2CO316.30g, 125ml of DMF and 26.70g of BrBn, reacting for 24h by magnetic stirring, filtering after the reaction is finished, concentrating the mother liquor to be dry, adding 300ml of isopropanol, heating to 70 ℃, carrying out heat filtration to remove insoluble substances, stirring the filtrate for 3-4h at normal temperature, filtering, leaching the filter cake with isopropanol, drying the filter cake under reduced pressure and constant weight to obtain 18.50g of white powder of the compound (2), wherein the yield is 46.25%. The hydrogen spectrum of compound (2) is shown in FIG. 1.
In other examples, compound (2) may be prepared by adding 300ml of isopropanol, heating to 80 ℃ or 75 ℃, and then filtering off insoluble substances.
Example 2
The preparation of compound (3) comprises the following steps:
at normal temperature, in a 250ml reaction bottle, adding about 70ml of pyridine and 18.50g of compound (2) in sequence, controlling the temperature within the range of 20-25 ℃ after adding, dropwise adding 37.50g of acetic anhydride, then adding about 0.2g of 4-Dimethylaminopyridine (DMAP), maintaining the temperature at 20-25 ℃, stirring for reacting overnight, pouring the reaction solution into a mixed solution of 350ml of purified water and 1850ml of ethyl acetate, standing for layering after adding, sequentially extracting and washing an organic layer with 200ml of 25.0% HCl aqueous solution and 200ml of 2 saturated sodium bicarbonate aqueous solution, drying the organic layer with anhydrous sodium sulfate, filtering, leaching, and concentrating under reduced pressure until dried to obtain 30.02g of colorless oily matter with the yield of 106.4%. Purification was performed by column chromatography (n-heptane to n-heptane/ethyl acetate 1/2), and the objective component (developing solvent: ethyl acetate) was collected and concentrated under reduced pressure to dryness to obtain 14.50g of the compound (3) as a white powder. The hydrogen spectrum of compound (3) is shown in FIG. 2.
Example 3
The preparation of compound (4) comprises the following steps:
normal temperature, N2Under protection, 13.20g of the compound (3) and 265ml of ethyl acetate are sequentially added into a 1000ml reaction bottle, stirred, dissolved and clarified, the temperature is controlled to be 15-25 ℃, 14.46g of TMSOTf is dropwise added, the temperature is controlled to be 50-55 ℃, stirred and reacted for 2 hours, then the temperature is controlled to be 0-5 ℃, 11.0g of triethylamine is dropwise added, then 100ml of ice water is added, stirred for 10 minutes, kept stand and layered, an organic layer is extracted and washed twice by 100ml and 50ml of purified water, and the organic layer is dried by anhydrous sodium sulfate, filtered, leached and concentrated under reduced pressure to be dry to obtain colorless oily matter. Column chromatography purification (n-heptane-n-heptane/ethyl acetate 1/1-ethyl acetate) was performed to collect the objective component, and the product was concentrated under reduced pressure to dryness to obtain 9.14g of compound (4) as a colorless oil. The hydrogen spectrum of compound (4) is shown in FIG. 3.
Example 4
The preparation of compound (5) comprises the following steps:
at normal temperature, 9.80g of the compound (4), 40ml of toluene and benzyl alcohol (R) are added into a reaction flask in sequence1Benzyl) 20.0ml, stirring at room temperature under nitrogen protection, adding 60% NaH 0.04g, stirring for 30min, adding dibenzyl carbonate (R)1Benzyl) 24.22g is taken, stirred and reacted for 1h at 50 ℃, 0.032mol of glacial acetic acid is added to quench the reaction, the reaction is carried out on a column by a wet method, dichloromethane washes small polar impurities, dichloromethane/methanol is 40/1, the target component is washed, and the mixture is concentrated under reduced pressure to obtain the compound (5) white solid, 6.85g, yield is 87.96%. The yield is far higher than the yield (76.9%) of the compound (5) obtained by the two-step method in CN 101679339A. The hydrogen spectrum of compound (5) is shown in FIG. 4.
In the preparation example of the other compound (5), dibenzyl carbonate was added and the reaction was stirred at 55 ℃ for 2 hours. In other embodiments, the stirring reaction temperature may also be 10 ℃, 52 ℃, 60 ℃ or 80 ℃. The stirring reaction time can be adjusted within 30 min-24 h. The yield of the compound (5) was substantially the same as in example 4 by changing the above reaction temperature or time.
In other preparation examples of the compound (5), the toluene solvent may be replaced with any one or more of N, N-dimethylformamide, benzyl alcohol, N-heptane, methyl t-butyl ether, tetrahydrofuran, and 1, 4-dioxane.
In another production example of the compound (5), the compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 8: 30: 0.02: 36.
in another production example of the compound (5), the compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 12: 15: 0.1: 12.
in other embodiments, R1 can also be benzyl substituted with chloro, bromo, iodo, nitro, alkoxy, alkyl, or aryl; even R1 can be allyl.
Example 5
The preparation of compound (6) comprises the following steps:
N2under protection, sequentially adding 6.85g of compound (5), 28ml of THF and 7ml of DMF into a 250ml reaction bottle, stirring until the compound is dissolved and clarified after the addition is finished, controlling the temperature to be within the range of 0-5 ℃, adding 0.91g of 60% NaH in batches, maintaining the temperature to be 0-5 ℃, stirring for 30min after the addition is finished, adding 2.88g of dimethyl sulfate, maintaining the temperature, stirring for reaction overnight, then adding 100ml of toluene and 1.06g of glacial acetic acid for quenching reaction, and using 40ml of 25.0% NaHCO to react a reaction solution3The aqueous solution was extracted 2 times, the aqueous layer was extracted 2 times with 70ml of 2 toluene, all toluene layers were combined and dried over anhydrous sodium sulfate, filtered, rinsed, concentrated to near dryness, and purified by column chromatography (dichloromethane → dichloromethane/methanol 20/1) to give compound (6) as a colorless oil 8.0 g. The hydrogen spectrum of compound (6) is shown in FIG. 5.
Example 6
The preparation of compound (7) comprises the following steps:
N2under protection, 7.10g of the compound (6), 21ml of toluene and 7ml of tertiary butanol are sequentially added into a 100ml reaction bottle at room temperature, stirring is carried out until the mixture is dissolved and clarified, and TMSN is added34.10g and 1.55g of titanium isopropoxide, maintaining the temperature of 20-25 ℃, stirring for reaction for 24 hours, then filtering, draining the filtrate, rinsing with 10ml of methanol, and carrying out oil pump to dry the filter cake to obtain 5.76g of compound (7) as an off-white solid, wherein the yield is as follows: 72.6 percent.
Example 7
The preparation of compound (8) comprises the following steps:
and (3) at normal temperature, sequentially adding 5.00g of the compound (7) and 20ml of tetrahydrofuran into a 100ml reaction bottle, stirring until the mixture is dissolved, adding 3.24g of triphenylphosphine, heating to 40-50 ℃ after the addition is finished, stirring for reaction for 10min, performing TLC (DCM/ME ═ 10/1), allowing the raw materials to disappear, and cooling to room temperature to obtain a reaction solution of the compound (8).
Example 8
The preparation of compound (9) comprises the following steps:
to the reaction solution of the compound (8) in example 7, 12.5g of purified water and 5.40g of a 25% aqueous solution of NaOH were added, the reaction was performed with stirring at a temperature of 40 to 45 ℃ for 2 hours, TLC (DCM/ME ═ 10/1) was used, the starting material was cooled to room temperature, the mixture was allowed to stand for liquid separation, 6ml of thf was added to the aqueous layer for washing, about 4ml of concentrated hydrochloric acid was added dropwise to the aqueous layer, the PH was adjusted to 2 to 3, and the PH was adjusted to 9 to 10 with a 25% aqueous solution of NaOH to obtain a reaction solution of a compound (9).
Example 9
The preparation of compound (11) comprises the following steps:
to the reaction mixture of the compound (9) of example 8 was added 30ml of methanol and 3.82g of N, N' -bis (tert-butoxycarbonyl) -1H-pyrazole-1-carboxamidine (compound 10) at room temperature, and the mixture was stirred and reacted at 20 to 25 ℃ for 48 hours to adjust the pH to 8.5 to 8.8, the reaction mixture was concentrated to dryness, 100ml of ethyl acetate was added and the mixture was concentrated under reduced pressure to remove methanol, the concentrate was washed with 50ml of 3 ethyl acetate 3 times, the aqueous layer was adjusted to 2 to 3 with about 1.3g of concentrated hydrochloric acid, the aqueous layer was extracted with 50ml of 3 ethyl acetate, and the organic layers were combined and concentrated to dryness to obtain 5.20g of a white solid (compound 11) with a yield of 85.1%.
Example 10
The preparation of compound (12) comprises the following steps:
the compound (11) obtained in example 9 was added to 50ml of dichloromethane, 5g of trifluoroacetic acid was added to the mixture and reacted at room temperature for 3 hours, the mixture was concentrated to dryness under reduced pressure, 25ml of purified water was added, and the mixture was adjusted to pH 6 to 8 with 10% aqueous sodium hydroxide solution. Adding 50ml of methanol, stirring at normal temperature for crystallization, filtering, leaching filter cakes with methanol, and drying at 40 ℃ under reduced pressure to obtain 2.74g of compound (12) white powder with the yield of 70.62%. The hydrogen spectrum of compound (12) is shown in FIG. 7.
Example 11
Normal temperature, N2Under protection, 2.00g of the compound (12), 10ml of methanol and 3.54g of the compound 13 are sequentially added into a 100ml reaction flask, finally 10.5ml of a methanol solution of HCl (1N hydrogen chloride) is added, the mixture is clarified, the temperature is maintained at 20-25 ℃, the mixture is stirred for reaction for 1 hour, reduced pressure concentration and near drying are carried out, 20ml of purified water is added, 20ml of ethyl acetate is used for extraction and washing for three times, the pH value of a water layer is adjusted to be 7 by saturated sodium carbonate, the mixture is stirred for 1 hour, then, the pH value is adjusted to be 8.5-9.0 by saturated sodium carbonate, the mixture is stirred for 3 hours, the pH value is adjusted to be 5-6 by 6N hydrochloric acid, the mixture is stirred for 30 minutes, filtered, filter cake is rinsed by purified water, the filter cake is 35 ℃, and the mixture is dried under reduced pressure to a constant weight, and 2.34g of the compound (I) white powder is obtained, the yield is 85.6%, and the HPLC is 99.84%.
Compound 13 in this example can be replaced with Compound 14, with the other conditions remaining unchanged.
Comparative example 1
This comparative example differs from example 4 only in that dibenzyl carbonate is replaced with carbonyldiimidazole. The product has more impurities, column chromatography is needed, and the yield of the finally obtained compound (5) is only 20%.
Comparative example 2
This comparative example differs from example 4 only in that dibenzyl carbonate was replaced with benzyl chloroformate. The yield of the compound (5) finally obtained is only 25% due to the fact that column chromatography is required because of a large amount of impurities.
Various other modifications and changes may be made by those skilled in the art based on the above-described technical solutions and concepts, and all such modifications and changes should fall within the scope of the claims of the present invention.

Claims (10)

1. A method for preparing a lanimivir octanoate intermediate by a one-pot method is characterized by comprising the following steps:
Figure FDA0002535817490000011
wherein R is1Is benzyl, substituted benzyl or allyl.
2. The method of claim 1, comprising the steps of: mixing a compound represented by the formula (4) with an organic solvent R1OH is mixed and stirred, then NaH is added under the protection of nitrogen, stirring is carried out for 30-60 min, and then (R) is added1O)2And (3) stirring CO at the temperature of 0-80 ℃ for reaction for 30 min-24 h, and then separating to obtain the compound shown in the formula (5).
3. The method according to claim 2, wherein the reaction temperature is 10 to 60 ℃.
4. The method according to claim 3, wherein the reaction temperature is 50 to 55 ℃.
5. The method according to claim 2, wherein the reaction time is 30min to 5 h.
6. The method according to claim 2, wherein the organic solvent is any one or more of toluene, N-dimethylformamide, benzyl alcohol, N-heptane, methyl tert-butyl ether, tetrahydrofuran and 1, 4-dioxane.
7. The method according to claim 1, wherein the NaH is present at a concentration of 60% by mass.
8. The method of any one of claims 1-7, wherein R is1Is benzyl.
9. The method according to claim 1, wherein the compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 8-12: 15-30: 0.02-0.1: 12-36.
10. The method according to claim 9, wherein the compound represented by the formula (4), R1OH、NaH、(R1O)2The mass ratio of CO is 9.8: 20: 0.04: 24.22.
CN202010532321.1A 2020-06-12 2020-06-12 Method for preparing lanimivir octanoate intermediate by one-pot method Pending CN113801138A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010532321.1A CN113801138A (en) 2020-06-12 2020-06-12 Method for preparing lanimivir octanoate intermediate by one-pot method
PCT/CN2020/120751 WO2021248764A1 (en) 2020-06-12 2020-10-14 Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010532321.1A CN113801138A (en) 2020-06-12 2020-06-12 Method for preparing lanimivir octanoate intermediate by one-pot method

Publications (1)

Publication Number Publication Date
CN113801138A true CN113801138A (en) 2021-12-17

Family

ID=78846846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010532321.1A Pending CN113801138A (en) 2020-06-12 2020-06-12 Method for preparing lanimivir octanoate intermediate by one-pot method

Country Status (2)

Country Link
CN (1) CN113801138A (en)
WO (1) WO2021248764A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417297B (en) * 2007-04-11 2013-12-01 Daiichi Sankyo Co Ltd Neuraminic acid derivatives and method for manufacturing thereof
CN102532080A (en) * 2010-12-29 2012-07-04 中国科学院上海药物研究所 Novel sialic acid derivant, preparation method thereof, drug composite comprising the same and application thereof
CN105037309A (en) * 2011-12-16 2015-11-11 第一三共株式会社 Method for producing neuraminic acid derivative
CN103435582B (en) * 2013-06-28 2015-09-16 深圳海王药业有限公司 A kind of preparation method of La Nina meter Wei monooctyl ester
CN105085455A (en) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 Sialic acid analogues or pharmaceutically acceptable salts and application thereof
MX2021002569A (en) * 2018-09-06 2021-06-08 Cidara Therapeutics Inc Compositions and methods for the treatment of viral infections.

Also Published As

Publication number Publication date
WO2021248764A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CN103570696B (en) A kind of preparation method of Axitinib intermediate and preparing the application in Axitinib
CN111233930B (en) Preparation method of Reidesciclovir
CN109956870A (en) A kind of Luo Shasi his synthetic method and its midbody compound
CN105198718A (en) Preparation method for buparvaquone
CN103204801A (en) Synthesis method for N-Boc-3-piperidone
EP2935255A1 (en) A process for preparation of rivaroxaban
CN112321467A (en) Preparation method of (2S,3R) -p-methylsulfonylphenylserine ethyl ester
CN113801138A (en) Method for preparing lanimivir octanoate intermediate by one-pot method
CN113801082A (en) Preparation method of lanimivir octanoate
CN112961198B (en) Preparation method of purine nucleotide intermediate
CN107383062A (en) The ANCE of Ceftibuten parent nucleus 7 preparation method
CN102491992A (en) Method for preparing carbapenem type antibiotic key intermediate 4-BMA
CN111499675A (en) Synthetic method of fludarabine phosphate
CN113667006B (en) Preparation method of cable Ma Lutai dipeptide side chain
CN107629039A (en) The preparation method and intermediate of deuterated acrylamide
CN113754630B (en) Synthetic method of alpha-lipoic acid
CN111533699B (en) Synthesis method of 2- (trifluoromethyl) pyrimidine-5-alcohol
CN111635368B (en) Preparation method of amine compound
CN108059608A (en) A kind of preparation method of Ezetimibe
CN115010593A (en) Synthetic method of 3-methyl bicyclo [1.1.1] pentane-1-carboxylic acid
CN115974864A (en) Synthetic method of 2- (3-azetidinyl) thiazole salt
CN106432227A (en) Pirenzepine hydrochloride key intermediate preparation method
CN103819402B (en) Dust is for drawing Wei intermediate and its preparation method and application
CN101735106B (en) Method for preparing biphenyl compound
CN113754597A (en) Benzhydrylpiperazine compound containing linear chain olefin and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 215123 building C25, nanotechnology Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province

Applicant after: BRIGHTGENE BIO-MEDICAL TECHNOLOGY Co.,Ltd.

Applicant after: Borui Pharmaceutical (Suzhou) Co.,Ltd.

Address before: 215123 building C25, nanotechnology Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province

Applicant before: BRIGHTGENE BIO-MEDICAL TECHNOLOGY Co.,Ltd.

Applicant before: XINTAI PHARMACEUTICAL (SUZHOU) Co.,Ltd.

CB02 Change of applicant information